Orchestra BioMed Holdings Files 8-K

Ticker: OBIO · Form: 8-K · Filed: Mar 7, 2024 · CIK: 1814114

Orchestra Biomed Holdings, Inc. 8-K Filing Summary
FieldDetail
CompanyOrchestra Biomed Holdings, Inc. (OBIO)
Form Type8-K
Filed DateMar 7, 2024
Risk Levellow
Pages2
Reading Time2 min
Key Dollar Amounts$0.0001
Sentimentneutral

Sentiment: neutral

Topics: 8-K, financial-reporting, regulation-fd

TL;DR

Orchestra BioMed filed an 8-K on March 6th, check for financial updates.

AI Summary

Orchestra BioMed Holdings, Inc. filed an 8-K on March 6, 2024, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known as Health Sciences Acquisitions Corp 2, is incorporated in Delaware and headquartered in New Hope, Pennsylvania.

Why It Matters

This filing provides updates on Orchestra BioMed's regulatory disclosures and financial reporting, which are crucial for investors to assess the company's current status and performance.

Risk Assessment

Risk Level: low — This is a routine filing of an 8-K, primarily containing financial statements and exhibits, with no immediate indication of significant new risks.

Key Numbers

  • 001-39421 — Commission File Number (Identifies the company's filing with the SEC)
  • 92-2038755 — IRS Employer Identification No. (Company's tax identification number)

Key Players & Entities

  • Orchestra BioMed Holdings, Inc. (company) — Registrant
  • Health Sciences Acquisitions Corp 2 (company) — Former company name
  • March 6, 2024 (date) — Date of earliest event reported
  • Delaware (jurisdiction) — State of incorporation
  • New Hope, Pennsylvania (location) — Principal executive offices

FAQ

What specific financial statements are included in this 8-K filing?

The filing indicates that 'Financial Statements and Exhibits' are included, but the specific details of these statements are not provided in the excerpt.

What is the significance of the 'Regulation FD Disclosure' item?

Regulation FD (Fair Disclosure) ensures that material information is disclosed to the public simultaneously, preventing selective disclosure to analysts or institutional investors.

When did Orchestra BioMed Holdings, Inc. change its name from Health Sciences Acquisitions Corp 2?

The date of the name change was June 3, 2020.

What is the primary business of Orchestra BioMed Holdings, Inc. based on its SIC code?

The Standard Industrial Classification (SIC) code 3841 indicates the company is in the 'Surgical & Medical Instruments & Apparatus' industry.

Where are Orchestra BioMed Holdings, Inc.'s principal executive offices located?

The principal executive offices are located at 150 Union Square Drive, New Hope, Pennsylvania, 18938.

Filing Stats: 529 words · 2 min read · ~2 pages · Grade level 10.4 · Accepted 2024-03-06 19:48:48

Key Financial Figures

  • $0.0001 — h registered Common stock, par value $0.0001 per share OBIO The Nasdaq Global Mark

Filing Documents

01

Item 7.01. Regulation FD Disclosure. A copy of a slide presentation that Orchestra BioMed Holdings, Inc. (the "Company") uses at investor and industry conferences and presentations is attached to this Current Report on Form 8-K ("Current Report") as Exhibit 99.1 and is incorporated herein solely for purposes of this Item 7.01 disclosure. The information in Item 7.01 of this Current Report, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of such section. The information in Item 7.01 of this Current Report, including Exhibit 99.1, shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any incorporation by reference language in any such filing.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Investor Presentation . 104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). 2

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ORCHESTRA BIOMED HOLDINGS, INC. By: /s/ David Hochman Name: David P. Hochman Title: Chief Executive Officer Date: March 6, 2024 3

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.